SKI Market

Indian Indices

Sensex

84,065.75 485.35
( 0.58%)

Global Indices

Nasdaq

50,145.69 1,215.96
(2.49%)

Dow Jones

6,954.50 135.10
(1.98%)

Hang Seng

56,676.08 2,422.40
(4.46%)

Nikkei 225

10,359.93 50.71
(0.49%)

Forex

USD-INR

90.32 -0.07
(-0.08%)

EUR-INR

106.52 -0.28
(-0.26%)

GBP-INR

122.68 -1.05
(-0.85%)

JPY-INR

0.58 0.00
(-0.33%)

YOU ARE HERE :
HOME
Markets
Equity
Company News Details

EQUITY - MARKET SCREENER

Alivus Life Sciences Ltd

Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln

BSE Code

ISIN Demat

Book Value()

543322

INE03Q201024

245.6784213

NSE Symbol

P/E(TTM)

Mar.Cap( Cr.)

ALIVUS

20.32

11429.21

EPS(TTM)

Face Value()

Div & Yield %

45.82

0.54

Back

Accel consolidated net profit rises 2.56% in the September 2025 quarter

Nov 13,2025

Net profit of Accel rose 2.56% to Rs 0.80 crore in the quarter ended September 2025 as against Rs 0.78 crore during the previous quarter ended September 2024. Sales rose 11.13% to Rs 43.65 crore in the quarter ended September 2025 as against Rs 39.28 crore during the previous quarter ended September 2024.

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	43.65	39.28	11
OPM %	7.51	9.01	-
PBDT	2.02	2.44	-17
PBT	0.34	0.94	-64
NP	0.80	0.78	3

84,065.75 485.35 ( 0.58%)

50,145.69 1,215.96 (2.49%)

6,954.50 135.10 (1.98%)

56,676.08 2,422.40 (4.46%)

10,359.93 50.71 (0.49%)

90.32 -0.07 (-0.08%)

106.52 -0.28 (-0.26%)

122.68 -1.05 (-0.85%)

0.58 0.00 (-0.33%)